Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis

John M. Vierling, Masoud Mokhtarani, Robert S. Brown, Parvez Mantry, Don C. Rockey, Marwan Ghabril, Richard Rowell, Marzena Jurek, Dion F. Coakley, Bruce F. Scharschmidt

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background & Aims: There is controversy over the use of measuring blood levels of ammonia (NH3) in the management of patients with overt hepatic encephalopathy (HE). Methods: We performed a retrospective analysis of data from a randomized, double-blind study of 178 patients with cirrhosis given glycerol phenylbutyrate (an NH3-lowering agent) or placebo for 16 weeks. Blood samples were collected at baseline and on study days 7 and 14 and NH3 levels were measured. The probabilities of having an HE episode, based on ammonia values, were modeled using binary logistic regression. A Cox proportional model was used to determine the risk of HE episodes in patients with baseline fasting NH3 levels ≤1.5-fold the upper limit of normal (ULN) versus patients with fasting NH3 levels >1.5-fold the ULN. Results: The risk and frequency of HE episodes and HE-related hospitalizations correlated with baseline (mean, 51 ± 6 μmol/L; ULN, 35 μmol/L) and on-study fasting levels of NH3, and increased sharply at levels >1.5-fold the ULN. Regardless of baseline level, NH3 exposure and the relative risk of HE episodes were decreased by glycerol phenylbutyrate. Conclusions: In analysis of data from a phase 2 study of the effects of glycerol phenylbutyrate in patients with cirrhosis, we found that fasting levels of NH3 in blood can identify patients at risk for HE-related morbidity. Patients with HE might benefit from NH3-lowering therapy. ClinicalTrials.gov no: NCT 00999167.

Original languageEnglish (US)
JournalClinical Gastroenterology and Hepatology
DOIs
StateAccepted/In press - 2016

Fingerprint

Hepatic Encephalopathy
Ammonia
Fasting
Fibrosis
Proportional Hazards Models
Double-Blind Method
Hospitalization
Logistic Models
Placebos
Morbidity

Keywords

  • Cirrhosis Complications
  • GPB
  • Neurocognitive Function
  • Pharmacoeconomics
  • Portal Hypertension

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis. / Vierling, John M.; Mokhtarani, Masoud; Brown, Robert S.; Mantry, Parvez; Rockey, Don C.; Ghabril, Marwan; Rowell, Richard; Jurek, Marzena; Coakley, Dion F.; Scharschmidt, Bruce F.

In: Clinical Gastroenterology and Hepatology, 2016.

Research output: Contribution to journalArticle

Vierling, John M. ; Mokhtarani, Masoud ; Brown, Robert S. ; Mantry, Parvez ; Rockey, Don C. ; Ghabril, Marwan ; Rowell, Richard ; Jurek, Marzena ; Coakley, Dion F. ; Scharschmidt, Bruce F. / Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis. In: Clinical Gastroenterology and Hepatology. 2016.
@article{dca95b9a9cf3453d857ba5be8d329160,
title = "Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis",
abstract = "Background & Aims: There is controversy over the use of measuring blood levels of ammonia (NH3) in the management of patients with overt hepatic encephalopathy (HE). Methods: We performed a retrospective analysis of data from a randomized, double-blind study of 178 patients with cirrhosis given glycerol phenylbutyrate (an NH3-lowering agent) or placebo for 16 weeks. Blood samples were collected at baseline and on study days 7 and 14 and NH3 levels were measured. The probabilities of having an HE episode, based on ammonia values, were modeled using binary logistic regression. A Cox proportional model was used to determine the risk of HE episodes in patients with baseline fasting NH3 levels ≤1.5-fold the upper limit of normal (ULN) versus patients with fasting NH3 levels >1.5-fold the ULN. Results: The risk and frequency of HE episodes and HE-related hospitalizations correlated with baseline (mean, 51 ± 6 μmol/L; ULN, 35 μmol/L) and on-study fasting levels of NH3, and increased sharply at levels >1.5-fold the ULN. Regardless of baseline level, NH3 exposure and the relative risk of HE episodes were decreased by glycerol phenylbutyrate. Conclusions: In analysis of data from a phase 2 study of the effects of glycerol phenylbutyrate in patients with cirrhosis, we found that fasting levels of NH3 in blood can identify patients at risk for HE-related morbidity. Patients with HE might benefit from NH3-lowering therapy. ClinicalTrials.gov no: NCT 00999167.",
keywords = "Cirrhosis Complications, GPB, Neurocognitive Function, Pharmacoeconomics, Portal Hypertension",
author = "Vierling, {John M.} and Masoud Mokhtarani and Brown, {Robert S.} and Parvez Mantry and Rockey, {Don C.} and Marwan Ghabril and Richard Rowell and Marzena Jurek and Coakley, {Dion F.} and Scharschmidt, {Bruce F.}",
year = "2016",
doi = "10.1016/j.cgh.2015.11.018",
language = "English (US)",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis

AU - Vierling, John M.

AU - Mokhtarani, Masoud

AU - Brown, Robert S.

AU - Mantry, Parvez

AU - Rockey, Don C.

AU - Ghabril, Marwan

AU - Rowell, Richard

AU - Jurek, Marzena

AU - Coakley, Dion F.

AU - Scharschmidt, Bruce F.

PY - 2016

Y1 - 2016

N2 - Background & Aims: There is controversy over the use of measuring blood levels of ammonia (NH3) in the management of patients with overt hepatic encephalopathy (HE). Methods: We performed a retrospective analysis of data from a randomized, double-blind study of 178 patients with cirrhosis given glycerol phenylbutyrate (an NH3-lowering agent) or placebo for 16 weeks. Blood samples were collected at baseline and on study days 7 and 14 and NH3 levels were measured. The probabilities of having an HE episode, based on ammonia values, were modeled using binary logistic regression. A Cox proportional model was used to determine the risk of HE episodes in patients with baseline fasting NH3 levels ≤1.5-fold the upper limit of normal (ULN) versus patients with fasting NH3 levels >1.5-fold the ULN. Results: The risk and frequency of HE episodes and HE-related hospitalizations correlated with baseline (mean, 51 ± 6 μmol/L; ULN, 35 μmol/L) and on-study fasting levels of NH3, and increased sharply at levels >1.5-fold the ULN. Regardless of baseline level, NH3 exposure and the relative risk of HE episodes were decreased by glycerol phenylbutyrate. Conclusions: In analysis of data from a phase 2 study of the effects of glycerol phenylbutyrate in patients with cirrhosis, we found that fasting levels of NH3 in blood can identify patients at risk for HE-related morbidity. Patients with HE might benefit from NH3-lowering therapy. ClinicalTrials.gov no: NCT 00999167.

AB - Background & Aims: There is controversy over the use of measuring blood levels of ammonia (NH3) in the management of patients with overt hepatic encephalopathy (HE). Methods: We performed a retrospective analysis of data from a randomized, double-blind study of 178 patients with cirrhosis given glycerol phenylbutyrate (an NH3-lowering agent) or placebo for 16 weeks. Blood samples were collected at baseline and on study days 7 and 14 and NH3 levels were measured. The probabilities of having an HE episode, based on ammonia values, were modeled using binary logistic regression. A Cox proportional model was used to determine the risk of HE episodes in patients with baseline fasting NH3 levels ≤1.5-fold the upper limit of normal (ULN) versus patients with fasting NH3 levels >1.5-fold the ULN. Results: The risk and frequency of HE episodes and HE-related hospitalizations correlated with baseline (mean, 51 ± 6 μmol/L; ULN, 35 μmol/L) and on-study fasting levels of NH3, and increased sharply at levels >1.5-fold the ULN. Regardless of baseline level, NH3 exposure and the relative risk of HE episodes were decreased by glycerol phenylbutyrate. Conclusions: In analysis of data from a phase 2 study of the effects of glycerol phenylbutyrate in patients with cirrhosis, we found that fasting levels of NH3 in blood can identify patients at risk for HE-related morbidity. Patients with HE might benefit from NH3-lowering therapy. ClinicalTrials.gov no: NCT 00999167.

KW - Cirrhosis Complications

KW - GPB

KW - Neurocognitive Function

KW - Pharmacoeconomics

KW - Portal Hypertension

UR - http://www.scopus.com/inward/record.url?scp=84975743734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975743734&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2015.11.018

DO - 10.1016/j.cgh.2015.11.018

M3 - Article

C2 - 26707685

AN - SCOPUS:84975743734

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

ER -